A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

July 2, 2021

Study Completion Date

December 6, 2021

Conditions
PsoriasisPlaque Psoriasis
Interventions
DRUG

EDP1815

EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

DRUG

Placebo

Placebo oral capsule

Trial Locations (29)

1036

Synexus Budapest - Magyarország Egészségügyi Szolgáltató Kft, Budapest

8900

Synexus Zalaegerszeg Magyarország Egészségügyi Kft, Zalaegerszeg

29621

Synexus Clinical Research US, Inc. - Anderson, Anderson

32162

Synexus Clinical Research US, Inc. - The Villages, The Villages

32806

Synexus Clinical Research US, Inc. - Orlando, Orlando

33624

ForCare Clinical Research, Tampa

33781

Synexus Clinical Research US, Inc. - St. Petersburg, St. Petersburg

45236

Synexus Clinical Research US, Inc. - Cincinnati, Cincinnati

95405

Synexus Clinical Research US, Inc. - Santa Rosa, Santa Rosa

97223

Oregon Medical Research Center PC, Portland

60-702

Synexus - Poznan, Poznan

50-088

Synexus - Wroclaw, Wroclaw

80-382

Synexus - Gdansk, Gdansk

81-537

Synexus - Gdynia, Gdynia

42-202

Synexus - Czestochowa, Częstochowa

40-040

Synexus - Katowice, Katowice

Unknown

Synexus - Lodz, Lodz

01-192

Synexus - Warszawa, Warsaw

RG2 0TG

Synexus - Thames Valley Clinical Research Centre, Reading

FY2 0JH

MAC Clinical Research, Blackpool

PR7 7NA

Synexus - Lancashire Clinical Research Centre, Chorley

L22 0LG

Synexus - Merseyside Clinical Research Centre, Waterloo

M23 9QZ

Medicine Evaluation Unit, Wythenshawe

TS17 6EW

MAC Clinical Research, Stockton-on-Tees

WS11 0BN

MAC Clinical Research, Cannock

CF15 9SS

Synexus - Wales Clinical Research Centre, Cardiff

LS10 1DU

MAC Clinical Research, Leeds

G20 0SP

Synexus - Scotland Clinical Research Centre, Glasgow

M15 6SE

Synexus - Manchester Clinical Research Centre, Manchester

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis | Biotech Hunter | Biotech Hunter